Citadel Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Citadel Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$515K	Sell	6,700 -1,300	-16%	-$101K	﹤0.01%	9233
2025 Q4	$632K	Buy	8,000 +1,000	+14%	+$86.6K	﹤0.01%	8455
2025 Q3	$641K	Sell	7,000 -600	-8%	-$48.9K	﹤0.01%	8530
2025 Q2	$496K	Sell	7,600 -1,000	-12%	-$65.1K	﹤0.01%	8658
2025 Q1	$576K	Sell	8,600 -2,200	-20%	-$131K	﹤0.01%	8170
2024 Q4	$597K	Buy	10,800 +3,800	+54%	+$218K	﹤0.01%	8169
2024 Q3	$418K	Sell	7,000 -700	-9%	-$42.7K	﹤0.01%	8648
2024 Q2	$490K	Sell	7,700 -2,800	-27%	-$182K	﹤0.01%	8081
2024 Q1	$726K	Buy	10,500 +6,100	+139%	+$368K	﹤0.01%	7592
2023 Q4	$243K	Sell	4,400 -400	-8%	-$22K	﹤0.01%	9583
2023 Q3	$279K	Buy	4,800 +700	+17%	+$40.4K	﹤0.01%	9307
2023 Q2	$221K	Sell	4,100 -1,700	-29%	-$75.4K	﹤0.01%	9671
2023 Q1	$230K	Buy	5,800 +2,700	+87%	+$114K	﹤0.01%	9923
2022 Q4	$125K	Buy	+3,100	New	+$116K	﹤0.01%	10887
2022 Q3	–	Sell	-7,800	Closed	-$231K	–	12535
2022 Q2	$231K	Sell	7,800 -4,800	-38%	-$138K	﹤0.01%	10393
2022 Q1	$354K	Sell	12,600 -5,200	-29%	-$194K	﹤0.01%	10199
2021 Q4	$820K	Buy	17,800 +6,000	+51%	+$258K	﹤0.01%	8428
2021 Q3	$387K	Buy	11,800 +3,100	+36%	+$96.4K	﹤0.01%	10488
2021 Q2	$305K	Buy	+8,700	New	+$296K	﹤0.01%	11217
2020 Q2	–	Sell	-6,200	Closed	-$253K	–	9722
2020 Q1	$253K	Buy	6,200 +900	+17%	+$47.9K	﹤0.01%	7614
2019 Q4	$327K	Sell	5,300 -2,000	-27%	-$132K	﹤0.01%	7454
2019 Q3	$532K	Sell	7,300 -7,000	-49%	-$524K	﹤0.01%	6630
2019 Q2	$1.18M	Buy	14,300 +1,700	+13%	+$121K	﹤0.01%	5438
2019 Q1	$889K	Buy	+12,600	New	+$741K	﹤0.01%	5795
2018 Q4	–	Sell	-7,300	Closed	-$413K	–	9044
2018 Q3	$413K	Buy	7,300 +900	+14%	+$55.1K	﹤0.01%	7008
2018 Q2	$428K	Sell	6,400 -30,400	-83%	-$1.9M	﹤0.01%	6632
2018 Q1	$2.14M	Buy	36,800 +5,600	+18%	+$355K	﹤0.01%	3633
2017 Q4	$2.01M	Buy	31,200 +14,800	+90%	+$921K	﹤0.01%	3621
2017 Q3	$861K	Buy	16,400 +7,600	+86%	+$362K	﹤0.01%	4524
2017 Q2	$412K	Buy	8,800 +3,000	+52%	+$145K	﹤0.01%	5402
2017 Q1	$287K	Sell	5,800 -5,000	-46%	-$281K	﹤0.01%	5940
2016 Q4	$655K	Buy	10,800 +5,200	+93%	+$318K	﹤0.01%	4484
2016 Q3	$372K	Sell	5,600 -900	-14%	-$56.3K	﹤0.01%	5327
2016 Q2	$363K	Sell	6,500 -7,800	-55%	-$379K	﹤0.01%	4943
2016 Q1	$481K	Buy	14,300 +6,200	+77%	+$210K	﹤0.01%	4467
2015 Q4	$366K	Sell	8,100 -11,100	-58%	-$478K	﹤0.01%	4919
2015 Q3	$759K	Buy	19,200 +7,000	+57%	+$398K	﹤0.01%	4190
2015 Q2	$757K	Sell	12,200 -4,200	-26%	-$250K	﹤0.01%	4355
2015 Q1	$1.03M	Buy	16,400 +14,300	+681%	+$870K	﹤0.01%	3886
2014 Q4	$118K	Buy	+2,100	New	+$92.6K	﹤0.01%	6501
2013 Q3	–	Sell	-533	Closed	-$3K	–	6700
2013 Q2	$3K	Buy	+533	New	+$3.73K	﹤0.01%	6383

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors's ANIP Position: Q1 2026 in Review

Citadel Advisors increased its ANI Pharmaceuticals (ANIP) stake by 464% in Q1 2026, buying an estimated $7.39M and bringing the position to 115,082 shares worth $8.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

Citadel Advisors first reported a position in ANIP in Q2 2013 and has held it in 43 quarters since. The position peaked at $53.1M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Citadel Advisors held 115,082 shares of ANI Pharmaceuticals worth $8.85M as of Q1 2026.
Citadel Advisors bought 94,667 ANI Pharmaceuticals shares in Q1 2026, an estimated $7.39M.
ANI Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3426 holding.
Citadel Advisors first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
Citadel Advisors's ANI Pharmaceuticals position peaked at $53.1M in Q3 2025.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.